Comparative Pharmacology
Head-to-head clinical analysis: AFAXIN versus ALTRENO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AFAXIN versus ALTRENO.
AFAXIN vs ALTRENO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of the sodium-dependent serotonin reuptake transporter (SERT), increasing serotonin levels in the synaptic cleft.
Unknown; believed to involve reduction of hepatic glucose production and improvement of insulin sensitivity via AMPK activation.
500 mg orally twice daily
ALTRENO is not a recognized drug. No data available.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults, allowing twice-daily dosing; prolonged in renal impairment (up to 30 hours).
Terminal elimination half-life is 20-30 hours; steady state reached in 5-7 days.
Clinical Note
moderateVenlafaxine + Desmopressin
"The risk or severity of adverse effects can be increased when Venlafaxine is combined with Desmopressin."
Clinical Note
moderateDesvenlafaxine + Desmopressin
"The risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Desmopressin."
Clinical Note
moderateDesvenlafaxine + Haloperidol
"The risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Haloperidol."
Clinical Note
moderateRenal excretion accounts for approximately 60-70% of the administered dose as unchanged drug; biliary/fecal elimination accounts for 20-25% with the remainder as metabolites.
Primarily renal (70-80% as unchanged drug), with 10-15% biliary/fecal elimination.
Category C
Category C
Retinoid
Retinoid
Venlafaxine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Venlafaxine."